3 Einträge |
Seite 1 / 1
![]() |
Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. |
Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, Kaufman B, Petruzelka L, Eniu A, Anghel R, Koynov K, Vrbanec D, Pienkowski T, Melichar B, Spanik S, Ahlers S, Messinger D, Inbar MJ, Zielinski C |
British journal of cancer. 2014 Sep 30. pii: bjc2014504. doi: 10.1038/bjc.2014.504. pmc: PMC4260030 |
PMID: 25268370 |
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine. |
Tomova A, Brodowicz T, Tzekova V, Timcheva C, Wiltschke C, Gerges DA, Pawlega J, Spanik S, Inbar MJ, Zielinski CC |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Jan 1. pii: 10.1200/jco.2008.26.15_suppl.1106 |
PMID: 27950867 |
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. |
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A |
The Lancet. Oncology. 2017 Nov 13. pii: S1470-2045(17)30717-9. doi: 10.1016/S1470-2045(17)30717-9 |
PMID: 29146401 |
3 Einträge |
Seite 1 / 1
![]() |